Dr. Olsson has more than 30 years of experience of inhaled formulations having spent about equal time on CMC and clinical pharmacology at his former employer, AstraZeneca.
In 2015 he took a position as senior inhalation consultant at Emmace Consulting AB. His specialty is IVIVC with particular emphasis on predicting in vivo outcomes, such as lung disposition, from in vitro data, and is a well-known author and speaker on this topic.
For many years he was part of the aerosol committees of USP and EP and member of industry groups such as IPAC-RS and EPAG.
He was part of the teams developing the multi-stage liquid impinger, the next generation impactor and the OPC mouth-throat models.
He is author and owner of the Mimetikos Preludium software.